Pharmacogenomic testing for mental health (Part I): documenting early adopter perceptions of use for eight scenarios.

Abstract

Aim: We sought to understand how early adopters used pharmacogenomic (PGx) testing for treating depression and attention deficient hyperactivity disorder (ADHD). Patients & methods: We conducted a phone survey with prescribers who had previously ordered an Informed PGx (Progenity, Inc., MI, USA) test. Results: We identified 1037 prescribers in our sampling period. Respondents (n\xa0=\xa064) were predominantly female (61.5%) and in pediatrics (n\xa0=\xa042; 64.6%). PGx testing was used for multiple scenarios (mean 3.3\xa0±\xa01.6); the most common was after no response to medication was observed (80%; 51/64). Most respondents state that test results typically reveal an altered metabolizer status. Conclusion: PGx test results ordered by early adopters often reveal altered metabolizers which leads them to change the depression/ADHD medication regimen. Future work should evaluate the clinical utility of PGx testing for depression/ADHD treatment.